(MRX) Marex Ordinary Shares - Ratings and Ratios
Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock •
MRX: Financial Derivatives, Commodities, Metals, Agricultural Products, Securities
Marex Group plc, traded on the NASDAQ under the ticker MRX, is a prominent player in financial infrastructure, specialising in liquidity provision, market access, and essential services across energy, commodities, and financial markets. Their operations are segmented into four key areas: Market Making, Clearing, Agency and Execution, and Hedging and Investment Solutions, each tailored to meet the diverse needs of their clients.
The companys Market Making segment ensures tight bid-ask spreads in metals, agricultural products, and energy, enhancing market efficiency. Their Clearing services offer risk management and operational support, crucial for institutions navigating complex markets. The Agency and Execution segment provides bespoke trade execution, leveraging expertise in commodities and energy markets to facilitate OTC trades seamlessly. Additionally, Marexs Hedging and Investment Solutions cater to institutional clients by offering custom OTC derivatives and risk management tools across agriculture, metals, energy, and currencies.
With a strong presence in the UK, US, and international markets, Marex serves a global clientele, including private banks, asset managers, pension funds, and corporates. Their structured notes business allows investors to craft tailored financial products across commodities, equities, foreign exchange, and fixed income, addressing the sophisticated needs of institutional investors.
Financially, Marex demonstrates stability with a market capitalization of $1.78 billion, a trailing P/E of 11.89, and a forward P/E of 9.34, indicating investor confidence and growth potential. Their price-to-book ratio of 2.02 and price-to-sales of 0.86 reflect a balanced valuation, appealing to both value and growth investors. This financial health underscores Marexs position as a reliable partner in global financial markets.
Additional Sources for MRX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MRX Stock Overview
Market Cap in USD | 1,785m |
Sector | Financial Services |
Industry | Capital Markets |
GiC Sub-Industry | Investment Banking & Brokerage |
IPO / Inception | 2024-04-25 |
MRX Stock Ratings
Growth 5y | 59.5% |
Fundamental | -7.57% |
Dividend | 11.6% |
Rel. Strength Industry | 57.7 |
Analysts | 4.5/5 |
Fair Price Momentum | 41.55 USD |
Fair Price DCF | 109.03 USD |
MRX Dividends
Dividend Yield 12m | 0.90% |
Yield on Cost 5y | 1.49% |
Annual Growth 5y | -100.00% |
Payout Consistency | 100.0% |
MRX Growth Ratios
Growth Correlation 3m | 95.1% |
Growth Correlation 12m | 96.6% |
Growth Correlation 5y | 96.6% |
CAGR 5y | 96.94% |
CAGR/Max DD 5y | 5.20 |
Sharpe Ratio 12m | 1.94 |
Alpha | 79.60 |
Beta | 0.85 |
Volatility | 46.31% |
Current Volume | 388.2k |
Average Volume 20d | 372.2k |
As of February 23, 2025, the stock is trading at USD 37.03 with a total of 388,244 shares traded.
Over the past week, the price has changed by +2.18%, over one month by +6.56%, over three months by +25.41% and over the past year by +96.94%.
Neither. Based on ValueRay Fundamental Analyses, Marex Ordinary Shares is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -7.57 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MRX as of February 2025 is 41.55. This means that MRX is currently undervalued and has a potential upside of +12.21% (Margin of Safety).
Marex Ordinary Shares has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy MRX.
- Strong Buy: 4
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, MRX Marex Ordinary Shares will be worth about 48.8 in February 2026. The stock is currently trading at 37.03. This means that the stock has a potential upside of +31.84%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 29.5 | -20.3% |
Analysts Target Price | 29.5 | -20.3% |
ValueRay Target Price | 48.8 | 31.8% |